News from us and our partners

Tags

Topics

0 results

News
22 June, 2026
Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases
News
22 June, 2026
deepc and University Hospital Basel Bring One of the World’s Most Widely Used Open-Source Medical AI Tools into Enterprise Healthcare Operations
News
22 June, 2026
Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis
News
18 June, 2026
F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis
News
18 June, 2026
Germany’s top research institutions and venture capital investors unite behind spin-off framework
News
10 June, 2026
Sofinnova Partners launches collaboration with AWS to scale AI across life sciences innovation
News
10 June, 2026
Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
News
9 June, 2026
Moon Surgical expands Maestro® platform into a multi-model physical AI platform with software Version 2.7
News
4 June, 2026
Muna Therapeutics Announces Nature Medicine Publication Validating Microglial State Transitions as Key Drivers of Alzheimer’s
News
3 June, 2026
Ingenix raises €13M led by Sofinnova to scale Modality Fusion AI
News
1 June, 2026
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
News
29 May, 2026
CorWave Achieves Major Regulatory Milestone with ISO 13485 Certification Across its Entire Operations
Feature
27 May, 2026
2025 Impact Report: focusing on the future of industrial biotech
News
26 May, 2026
NodThera Announces the Publication and Presentation of Cardiometabolic Clinical Data Supporting the Potential of Ruvonoflast to Treat Inflammation at the Source
News
26 May, 2026
Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer
News
26 May, 2026
P2 Science raises $23M to expand green chemistry platform

Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases

deepc and University Hospital Basel Bring One of the World’s Most Widely Used Open-Source Medical AI Tools into Enterprise Healthcare Operations

Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis

F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis

Germany’s top research institutions and venture capital investors unite behind spin-off framework

Sofinnova Partners launches collaboration with AWS to scale AI across life sciences innovation

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Moon Surgical expands Maestro® platform into a multi-model physical AI platform with software Version 2.7

Muna Therapeutics Announces Nature Medicine Publication Validating Microglial State Transitions as Key Drivers of Alzheimer’s

Ingenix raises €13M led by Sofinnova to scale Modality Fusion AI

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

CorWave Achieves Major Regulatory Milestone with ISO 13485 Certification Across its Entire Operations

2025 Impact Report: focusing on the future of industrial biotech

NodThera Announces the Publication and Presentation of Cardiometabolic Clinical Data Supporting the Potential of Ruvonoflast to Treat Inflammation at the Source

Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer

P2 Science raises $23M to expand green chemistry platform